Physician profile
Marilynn E Michaud
NPI 1942295035
$12,870.55
in general payments reported to CMS, 2019-2025
34 companies · $13.79 in 2025
The $13.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $1,282 · 2021: $1,974 · 2022: $2,306 · 2023: $3,109 · 2024: $2,387 · 2025: $13.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,430 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,429.74 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,286.30 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,178.28 | 2019-2024 | |
| Lilly USA, LLC | $1,108.98 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $1,089.29 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,063.89 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $920.99 | 2020-2024 | |
| Astellas Pharma US INC | $584.20 | 2019-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $533.31 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $486.72 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.53 | 2019-2024 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $390.96 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.44 | 2019-2024 | Xifaxan |
| Amgen INC. | $211.89 | 2019-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $185.22 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $144.67 | 2019-2025 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $141.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.02 | 2019-2022 | |
| Allergan, INC. | $128.54 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.53 | 2022 | |
| Merck Sharp & Dohme LLC | $95.11 | 2019-2022 | |
| Dynavax Technologies Corporation | $67.54 | 2023-2024 | Heplisav-B |
| Inspire Medical Systems, INC. | $44.13 | 2024 | Inspire |
| Eisai INC. | $30.87 | 2021 | |
| Xeris Pharmaceuticals, INC. | $26.86 | 2024 | Gvoke Hypopen |
| Neuronetics, INC. | $25.83 | 2019 | |
| Sumitomo Pharma America, INC. | $24.52 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $20.79 | 2021 | |
| Cequr Corporation | $18.39 | 2024 | Cequr Simplicity |
| Philips North America LLC | $18.22 | 2024 | (Ck7) Extended Holter |
| Corcept Therapeutics | $17.87 | 2024 | Korlym |
| Shield Therapeutics INC | $14.44 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.38 | 2023 | Quviviq |
| Amarin Pharma, INC. | $13.10 | 2019 | |
| Senseonics, Incorporated | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilynn Michaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.